Clinical Trials Directory

The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.

Stanford is now accepting new patients for this trial.



  • drug : Placebo
  • drug : Suvorexant

Phase: Phase 4


Ages Eligible For Study:

20 Years - 60 Years

Inclusion Criteria

- Aged 20-60 (older individuals excluded due to altered sleep-related circadian signaling) - Males and females - Shift worker - Minimum of three months of prior shift work - Will work minimum of four nights per week or 32 hours of night shift per week during study - "Night work" defined as having at least six hours of work occurring between 8 PM and 8 AM and no longer than 12 hours on shift - Presence of DSM-5 defined Circadian Rhythm Sleep-Wake Disorder: Shift Work Type - Insomnia (SE < 88%) during attempted daytime sleep or excessive sleepiness during nocturnal wake

External Links

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Yvonne Quevedo

Footer Links: